Contineum Therapeutics (CTNM) vs. Its Peers Critical Analysis

Contineum Therapeutics (NASDAQ:CTNM) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Contineum Therapeutics to similar businesses based on the strength of its valuation, dividends, risk, earnings, analyst recommendations, institutional ownership and profitability.

Earnings and Valuation

This table compares Contineum Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Contineum Therapeutics	$50.00 million	-$59.98 million	-6.08
Contineum Therapeutics Competitors	$5.38 billion	$3.23 billion	555.01

Contineum Therapeutics’ peers have higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Contineum Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Contineum Therapeutics’ peers have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Contineum Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1	2	3	0	2.33
Contineum Therapeutics Competitors	7819	13779	25785	1035	2.41

Contineum Therapeutics presently has a consensus target price of $21.50, indicating a potential upside of 99.63%. As a group, “Pharmaceuticals” companies have a potential upside of 24.26%. Given Contineum Therapeutics’ higher possible upside, research analysts clearly believe Contineum Therapeutics is more favorable than its peers.

Profitability

This table compares Contineum Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-25.48%	-24.28%
Contineum Therapeutics Competitors	-2,393.16%	-220.83%	-16.11%

Institutional & Insider Ownership

32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Contineum Therapeutics peers beat Contineum Therapeutics on 8 of the 12 factors compared.

About Contineum Therapeutics

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological, inflammatory and fibrotic diseases. The company is based in San Diego, California, and was previously known as Pipeline Therapeutics. Its development programs include PIPE-307, an investigational M1 receptor antagonist being studied for neurological conditions, including relapsing-remitting multiple sclerosis. Contineum is also developing PIPE-791, an investigational LPA1 receptor antagonist for fibrotic lung diseases and related conditions.